SG11201404014PA - Methods for increasing the infectivity of viruses - Google Patents

Methods for increasing the infectivity of viruses

Info

Publication number
SG11201404014PA
SG11201404014PA SG11201404014PA SG11201404014PA SG11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA SG 11201404014P A SG11201404014P A SG 11201404014PA
Authority
SG
Singapore
Prior art keywords
infectivity
viruses
increasing
methods
Prior art date
Application number
SG11201404014PA
Inventor
Brian Agnew
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of SG11201404014PA publication Critical patent/SG11201404014PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201404014PA 2012-01-26 2013-01-25 Methods for increasing the infectivity of viruses SG11201404014PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591023P 2012-01-26 2012-01-26
PCT/US2013/023045 WO2013112778A1 (en) 2012-01-26 2013-01-25 Methods for increasing the infectivity of viruses

Publications (1)

Publication Number Publication Date
SG11201404014PA true SG11201404014PA (en) 2014-08-28

Family

ID=48873928

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404014PA SG11201404014PA (en) 2012-01-26 2013-01-25 Methods for increasing the infectivity of viruses

Country Status (7)

Country Link
US (2) US20150017703A1 (en)
EP (1) EP2807251B1 (en)
KR (1) KR20140128966A (en)
CN (1) CN104220588A (en)
AU (1) AU2013212066B2 (en)
SG (1) SG11201404014PA (en)
WO (1) WO2013112778A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (en) 2011-12-16 2022-09-30 Modernatx Inc Modified mRNA compositions
KR20140129054A (en) 2012-01-26 2014-11-06 라이프 테크놀로지스 코포레이션 Methods for increasing the infectivity of viruses
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. Rna formulations
WO2019014924A1 (en) * 2017-07-21 2019-01-24 中国科学院深圳先进技术研究院 Virus transfection synergist and virus transfection applications based on click chemistry
MX2020002348A (en) 2017-08-31 2020-10-08 Modernatx Inc Methods of making lipid nanoparticles.
AU2020378643A1 (en) 2019-11-08 2022-06-02 Coave Therapeutics Modified adeno-associated virus vectors and delivery thereof into the central nervous system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820A (en) * 1846-10-21 Improvement in steam-engines
US7169411B1 (en) * 1997-06-13 2007-01-30 The University of Nebraska Board of Regents Composition for delivery of biological agents and methods for the preparation thereof
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
WO2001020989A1 (en) * 1999-09-22 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
WO2008029281A2 (en) * 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
JP2012508591A (en) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション Compositions and methods for manipulating cells
US20100203647A1 (en) * 2008-11-21 2010-08-12 The Rockefeller University Chemical Reporters of Protein Acylation

Also Published As

Publication number Publication date
US20180201907A1 (en) 2018-07-19
EP2807251B1 (en) 2018-01-10
KR20140128966A (en) 2014-11-06
EP2807251A1 (en) 2014-12-03
EP2807251A4 (en) 2015-08-12
AU2013212066B2 (en) 2018-11-08
US20150017703A1 (en) 2015-01-15
WO2013112778A1 (en) 2013-08-01
CN104220588A (en) 2014-12-17
AU2013212066A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
SG11201404014PA (en) Methods for increasing the infectivity of viruses
SG11201404361UA (en) Methods for increasing the infectivity of viruses
IL237275A0 (en) Compounds for the treatment of paramoxyvirus viral infectiones
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
GB201218933D0 (en) An entity
EP2806891A4 (en) Parainfluenza virus 5 based vaccines
GB201321144D0 (en) Improved oncolytic viruses
IL231132A0 (en) Viral clearnce methods
HK1212332A1 (en) Hepatitis c virus inhibitors
IL236450A0 (en) Process for the preparation of 5-fluoro-1h-pyrazoles
PL399419A1 (en) Process for the preparation of 4-methoxydihydrochalcone
PL399418A1 (en) Process for the preparation of 4-methoxydihydrochalcone
EP2887883A4 (en) Improved scalpel
KR101334557B9 (en) Cookware
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
GB201215184D0 (en) Therapeutic virus
ZA201405954B (en) Method for assessing the viability of viruses with lymphotropism
EP2826486A4 (en) Agent for the treatment of hepatitis c virus
GB201211930D0 (en) Concept for all killer viruses
HU229987B1 (en) Process for the preparation of pyrimidinyl-piperazines
GB201314063D0 (en) Virus
GB201213587D0 (en) Novel endolysin
GB201306812D0 (en) Virus